SBSanaba Boumbaly

Sanaba Boumbaly

*This is an algorithmically generated author record based on publicly available information.

Sanaba Boumbaly has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of location tracking methods to understand human-wildlife contact and pathogen spillover risks

    by Rebecca N. Lim, Joseph Akoi Boré, Tom Tipton, Amaziasizamoria Jumail, Milena Salgado-Lynn, Stephanie Key, Chelsea Baker, Edgar Manrique, Sanaba Boumbaly, Zézé Onivogui, et al.

    Background: Most emerging infectious diseases originate in wildlife populations. As demonstrated by recent epidemics and pandemics, pathogen spillover from zoonotic reservoirs can have devastating public health impacts. Contact between humans and wildlife reservoirs determines spillover risk, but these interactions remain poorly understood. Despite advancements in geolocation technology and its widespread integration into devices available to consumers and researchers, there are significant challenges to collecting fine-scale human movement data in remote areas to assess contact with wildlife. We aimed to evaluate available methods for collecting these data. We applied the findings to identify an optimal method for a case study on pathogen spillover from bats in rural communities of Macenta Prefecture, Republic of Guinea. Methods: Among existing methods for collecting location data from humans, we identified two methods as candidates for our case study: (1) a mobile device with the GPSLogger application and (2) a custom-designed wristwatch with geolocation technology. The spatial accuracy, battery life, and user experience of these methods were assessed under field conditions. This preliminary testing was conducted in remote, forested regions of Macenta, Guinea and Malaysian Borneo, which are areas with repeated zoonotic spillover events. Results: Overall, both methods enabled collection of fine-scale spatial data on human movement and proximity to wildlife habitats in remote, forested regions. From initial trials, the custom-designed wristwatch had greater accuracy, had longer battery life, and was reported by participants to be more comfortable to carry than the mobile devices. We demonstrated the utility of these methods for quantifying individual heterogeneities in space use and identifying areas and populations with high risk for human-wildlife contact. Conclusion: This proof-of-concept study provides evidence of the value of custom-designed location tracking watches, through their application in epidemiologic research in rural Guinea. However, mobile devices may be more accessible and suitable in contexts with high mobile phone usage and service coverage. Further research is needed to integrate these movement data with ecological and demographic data to understand how environment and human behaviour shape the dynamics of disease emergence.

  • Open Access

    Seroprevalence of viral hemorrhagic fevers and arboviral infections among febrile patients in Forest Guinea

    by Fara Raymond Koundouno, Youssouf Sidibe, Hugo Soubrier, Karifa Kourouma, Soua Koulemou, Tamba Elie Millimouno, Fernand M’Bemba Tolno, Saa Lucien Millimono, Kékoura Ifono, Faya Moriba Kamano, et al.

    Between 2017 and 2024, routine diagnostics surveillance in Guinea detected several confirmed viral hemorrhagic fever (VHF) cases among febrile patients. To assess exposure to Lassa virus and other viral pathogens, we conducted a retrospective cross-sectional seroprevalence study in Forest Guinea (Guéckédou and N’Zérékoré). Lassa virus seroprevalence was 56.0% in the Guéckédou study group and 29.8% in the N’Zérékoré study group. Seropositivity increased with age in both study groups, suggesting cumulative exposure. Samples from Guéckédou laboratory were also tested for other pathogens, and antibodies against Marburg virus (5.8%), Zika virus (5.4%) and Crimean-Congo haemorrhagic fever virus (1.2%) were detected.

  • Open Access

    Nosocomial Outbreak of Lassa Fever in Conakry, Guinea, 2022

    by Giuditta Annibaldis, Barré Soropogui, Kékoura Ifono, Jacob Camara, Mohamed Lamine Kaba, Fanta Berete, Sarah Ryter, Moussa Conde, Saa Lucien Millimono, Mette Hinrichs, et al.

    Background: Lassa fever is endemic in Guinea, with high seroprevalence in the forest region. However, clinical cases have been only anecdotally reported. In August 2022, a nosocomial outbreak occurred at a private clinic in the capital, Conakry, an area previously considered low risk. Methods: Suspected cases were confirmed by real-time reverse-transcription polymerase chain reaction within 24 hours. Viremia was monitored during hospitalization, and whole-genome sequencing was performed in-country within 13 days of outbreak detection. Outbreak investigation involved rodent testing in the home village of the suspected primary case. Results: Six cases were laboratory-confirmed, 5 of which were healthcare workers of the clinic. The case fatality rate was 16.7%. Viral RNA remained detectable in blood of survivors for a median of 26 days (interquartile range, 24–41 days) post–disease onset. Epidemiological investigations identified a suspected primary case, who had died of a febrile disease compatible with Lassa fever, had contact with all secondary cases, and had a travel history from Kissidougou area. Three near-complete and 1 partial Lassa virus genomes were recovered from the secondary cases, which phylogenetically clustered with genomes from central Guinea. Consistent with a common transmission source, the 4 genomes were almost identical. Rodent testing revealed a new reservoir area in eastern-central Guinea. Conclusions: This outbreak highlights the vulnerability of healthcare settings in low-prevalence areas of West Africa to nosocomial Lassa virus transmission due to human mobility. Facilitated by capacity-building programs for viral hemorrhagic fevers, rapid diagnosis, genomic analysis, and ecological assessment enabled an efficient outbreak response and control.


  • Open Access

    Genomic surveillance of Lassa virus in Guinea through in-country sequencing

    by Jacob Camara, Giuditta Annibaldis, Joon Klaps, Kékoura Ifono, Fara Raymond Koundouno, Youssouf Sidibé, Sarah Ryter, Moussa Conde, Saa Lucien Millimono, Mette Hinrichs, et al.

    Strengthening in-country sequencing capacity generated 28 Lassa virus genomes from human clinical cases, expanding our knowledge of Lassa fever in Guinea. Phylogeographic analysis revealed cross-border exchange between Liberia and the N’Zérékoré region, and a Sierra Leone introduction into the Guéckédou area. Enhanced genomic surveillance is crucial to guide future public health actions.


  • Open Access

    Emergence of mpox in Guinea: sporadic clade IIa cases and a clade IIb upsurge

    by Jacob Camara, Nils Peter Petersen, Fara Raymond Koundouno, Giuditta Annibaldis, Barré Soropogui, Sarah Ryter, Saa Lucien Millimono, Moussa Condé, Emily Victoria Nelson, Carolina van Gelder, et al.

    Background: Mpox virus (MPXV) has caused recurrent outbreaks in West Africa. However, Guinea had not previously reported laboratory-confirmed cases or MPXV genomic data. Methods: Suspected cases were identified in the N’Zérékoré region as well as in the Conakry (Sept 2024– Dec 2025) and confirmed by real-time PCR in regional and central laboratories, respectively. Whole-genome sequencing using nanopore technology was performed in-country, followed by phylogenetic and time-scaled evolutionary analyses. Findings: The first mpox case was clinically diagnosed in September 2024 in the N’Zérékoré region and laboratory-confirmed by the prefectural laboratory in Guéckédou. In total, seven cases were confirmed in Forest Guinea, of which five complete or almost complete MPXV genomes were recovered. All belonged to MPXV clade IIa. Genomic divergence, ancestral dating, and low APOBEC3-associated mutation frequencies were consistent with multiple independent zoonotic spillover events. In June 2025, one of the first mpox cases of an unfolding outbreak was confirmed in Conakry. Whole genome sequencing revealed MPXV clade IIb lineage G.1. By December 2025, the number of laboratory-confirmed mpox cases nationwide increased to 2,151. A total of nine outbreak strains were sequenced, all belonging to Clade IIb. The genomes clustered with contemporaneous genomes from Sierra Leone and showed high APOBEC3-associated mutation frequencies, suggesting sustained human-to-human transmission in the region. Interpretation: These data demonstrate simultaneous circulation of MPXV clade IIa and IIb strains in Guinea, likely resulting from zoonotic spillover and human-to-human transmission, respectively. Decentralised diagnostics and in-country sequencing facilitated rapid case confirmation and genomic surveillance, highlighting the importance of these critical capacities for outbreak preparedness and response. Funding: German Federal Ministry of Health and the German Center for Infection Research (DZIF).

  • Open Access

    Strengthening diagnostic capacity for viral hemorrhagic fevers in Forest Guinea: advances in Lassa fever case detection

    by Fara Raymond Koundouno, Youssouf Sidibe, Saa Lucien Millimono, Kékoura Ifono, Julia Hinzmann, Hugo Soubrier, Karifa Kourouma, Tamba Elie Millimouno, Fernand M’BEmba Tolno, Faya Moriba Kamano, et al.

    Viral hemorrhagic fevers (VHFs), including filoviruses, Lassa virus, yellow fever virus and dengue virus, remain a major public health threat in resource-limited settings. The 2014–2016 Ebola epidemic exposed critical gaps in laboratory preparedness and diagnostic capacity in most-at-risk countries, including Guinea. In order to implement sustainable in-country laboratory capacity for early detection and rapid response to VHF outbreaks, a decentralized diagnostics laboratory strengthening program started in the forested region of Guinea in Guéckédou (2017) and N’Zérékoré (2021). Between 2017 and 2024, a total of 4683 samples from suspected VHF cases were tested across the two laboratories. Of those, 47 (1%) were identified as positive for VHFs by molecular testing, including the 2021 Ebola virus disease resurgence and Marburg virus disease emergence samples, for which the laboratories supported rapid outbreak detection and case management. Notably, between 2020 and 2024, 30 Lassa fever cases were laboratory-confirmed with a case fatality rate of 67.9%. Of those, 66.7% were men, with 50.0% and 27.6% of the cases originating from the Guéckédou and N’Zérékoré prefecture, respectively. Prior to this program, Lassa fever detection in Guinea remained anecdotic. One case of yellow fever and one of dengue were also identified by molecular assays. The establishment of locally embedded laboratory infrastructure enhanced VHFs preparedness, surveillance, and response in Guinea. Beyond improving understanding of Lassa fever epidemiology, this program highlights the value of sustained laboratory capacity for early detection and health system resilience in VHF-endemic settings.


  • Open Access

    ViMOP: a user-friendly and field-applicable pipeline for untargeted viral genome nanopore sequencing

    by Nils Peter Petersen, Mia Le, Annick Renevey, Ehizojie Emua, Sarah Ryter, Giuditta Annibaldis, Jacob Camara, Sanaba Boumbaly, Cyril Erameh, Tanja Laske, et al.

    Motivation: Untargeted, also known as metagenomic, nanopore sequencing is a powerful tool for virus genomic surveillance, particularly in resource-limited settings and when paired with the portability of the MinION device (Oxford Nanopore Technologies, ONT). However, a major bottleneck for global access is the absence of a user-friendly software capable of efficiently analyzing untargeted nanopore sequencing data to generate high-quality consensus genomes. Results: We share ViMOP, a pipeline built on our long-term experience in nanopore field sequencing. The pipeline emphasizes field user-friendliness, flexibility and versatility to analyze reads generated directly from human clinical samples. The software assembles de novo contigs, matches contigs to known viral references and uses them to assemble consensus genomes. Executed with a single Nextflow command or via the EPI2ME Desktop interface (ONT), results are summarized in an HTML report. ViMOP, through its user-centered design, lowers the barrier to high-quality virus genome reconstruction and advances capacity for genomic surveillance. Availability and implementation: ViMOP is freely available for non-commercial use (https://github.com/opr-group-bnitm/vimop and https://zenodo.org/records/17913089), along with the associated database (https://zenodo.org/records/17652512), the scripts used to generate it (https://zenodo.org/records/17632662) and benchmarking code (https://zenodo.org/records/17633185).


  • Open Access

    Endemic Mycoses on the African Continent

    by A. V. Lipnitsky, A. A. Murugova, N. V. Polovets, E. V. Naidenova, A. Camara, M. S. Diallo, J.-C. Mobousse Misse, S. Boumbaly, M. S. Traore, I. I. Korsakova

    The review of the current microbiological, epidemiological and diagnostic aspects of some endemic mycoses (histoplasmosis, blastomycosis, emergomycosis) found on the African continent is brought forward. Other endemic mycoses (coccidioidomycosis, paracoccidioidomycosis, talaromycosis) have not been described in Africa and can only be imported. Histoplasmosis caused by Histoplasma capsulatum var. capsulatum is widespread in the world, but Africa is the only continent where two variants coexist – H. capsulatum and H. duboisii. The latter is the causative agent of the disease called “african histoplasmosis”. Disseminated forms of histoplasmosis are diagnosed in 5–20 % of HIV-infected individuals. African cases of blastomycosis are caused predominantly by Blastomyces percursus and B. emzantsi species, which differ significantly from the etiologic agents of this disease in North America (B. dermatitidis and B. gilchristii). The number of diagnosed cases of endemic mycoses in Africa has increased significantly in the last decade, which may be due to a new disease, emergomycosis. One of the etiologic agents of this mycosis is the dimorphic fungus Emergomyces africanus. Laboratory diagnostics of endemic mycoses in most African countries is limited due to the lack of experienced personnel and advanced test systems.

  • Open Access

    The results of the detection of specific IgG antibodies to Ebola virus (Filoviridae: Orthoebolavirus) in residents of the Republic of Guinea after the end of the epidemic

    by Ekaterina Naidenova, Mikhail Kartashov, Irina Shulgina, Stepan Pyankov, Maxim Kulagin, Mamadou Bah, Ibrahim Nourdine, Magassouba N’fally, Viktor Konomou, Mohamed Traore, et al.

    Introduction. In 2014–2016, an epidemic of Ebola virus disease (EVD) was registered in Guinea. In 2021, EVD cases were repeated in the region. The importance of studying the duration of post-infection immunity to the Ebola virus in the body of convalescents is due to the fact that after the end of the epidemic they can be the main sources of infection. One of the indicators of the pathogen circulation in a certain area is the detection of specific IgG antibodies in the blood sera of the inhabitants. The aim of the study is to identify IgG immunoglobulins to Ebola virus in the blood sera of reconvalescents and practically healthy residents of the Republic of Guinea after the end of the epidemic. Materials and methods. The ELISA method was used to test the blood sera of 9 patients treated at the NKDCEM hospital (Kindia), collected after the end of the disease and up to 72 months after recovery, and 3939 blood serum samples from practically healthy residents of Guinea. Results. IgG antibodies in the blood sera of reconvalescents a month after recovery were detected in a titer of up to 1 : 800. By 12 months, the antibody level decreased to 1 : 100 and remained at this level for up to 48 months. After 6 years of observation, no antibodies were registered. Among the 3939 blood samples from healthy residents, IgG immunoglobulins to the Ebola virus were detected in 5.6%. Most of the positive samples were collected in Forest Guinea (7.7%), and a smaller part in Upper Guinea (4.5%). The maximum percentage of positive samples was detected in people over 70 years of age (12.3%). Conclusion. In our case, it was shown that a high level of post-infection immunity in the blood sera of patients with EVD persists for the first 6 months, this corresponds to the data obtained by other authors, and does not exclude the possibility of re-infection. The highest level of the seroprevalence is registered in Forest Guinea. This indicates the active circulation of the pathogen and the constant contact of the inhabitants of the region with it, which leads to epidemiological complications.